Status:
UNKNOWN
The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
Lead Sponsor:
Sheba Medical Center
Collaborating Sponsors:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Neovascular Age Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
One concern about repeated intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in wet age related macular degeneration, is that in addition to blocking the proteins that trigge...
Eligibility Criteria
Inclusion
- Male or female in the ages of 50 year or older
- Willing and able to sign an inform consent
Exclusion
- Any history, signs or symptoms of any retinal or optic nerve disease, except AMD and mild hypertensive retinopathy
- In the presently bevacizumab/ranibizumab treated eye, prior PDT and/or intravitreal Kenalog, during the last 3 months.
- History of ocular surgery with the following exception: extra capsular cataract extraction with implantation of a posterior chamber intra-ocular lens.
- History of ocular laser treatment, with the following exceptions: Posterior capsulotomy following cataract surgery.
- Cataract or other media opacity precluding adequate fundus visualization of both eyes
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00640640
Start Date
August 1 2007
End Date
February 1 2009
Last Update
March 21 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Leuven
Leuven, Belgium
2
Goldschleger Eye Institute Sheba Medical Center
Ramat Gan, Israel, 52621